Dave Schulte
SVP, Managing Director @ McKesson Ventures
San Francisco, United States
Dave Schulte is a Series B investor at McKesson Ventures in San Francisco focused on Health Care and Information Technology. Dave has more than 15 years of experience, as an investor and investment banker, partnering with entrepreneurs to build innovative health care and technology businesses. He joined Kasier Permanente Ventures in 2003 and helped build KP's investment program. He is now responsible for managing the Fund's investment strategy and day to dayactivities. Prior to KP Ventures, Dave was a health care and software investment banker at J.P. Morgan, UBS, and Piper Jaffray.He serves or served as a Board Director or Observer for several companies: Atheromed, Baxano (sold to Trans1), Hemosphere (sold to Cryolife) , MetricStream, Nursefinders (sold to Goldman Sachs), Proteus Biomedical, Pulmonx, ValenTx, Valeritas and Xanitos. Dave is a graduate of St. John's University and earned a Master of Public Policy degree from Harvard University.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Dave Schulte invests in
Stages Dave Schulte invests in
Countries Dave Schulte invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 10 (59%)
- Information Technology 6 (35%)
- Software 4 (24%)
- Medical 3 (18%)
- Therapeutics 2 (12%)
Stage
- Series B 8 (47%)
- Series A 3 (18%)
- Series C 3 (18%)
- Series D 1 (6%)
- Series F 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $20M / Series A / Jan 07, 2026 | ||
| Lightship is a provider of enterprise-level, direct-to-patient clinical research solutions. The company engages patients at home from recruitment through completion and eliminates the hurdles and inefficiencies of traditional approaches. Founded in 2018, Lightship is based in El Segundo, California. | $40M / Series B / Oct 06, 2021 | ||
| IVX Health (IVXpress, Inc.) is a leading provider of infusion and injection therapy for those with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis and other conditions.IVX Health centers are conveniently located in the communities where patients live and offer flexible scheduling, includingevenings and weekends. Patients relax in their own private suite, equipped with high-speed Wi-Fi, a flat screen TV, and comfortable recliners with room for guests. IVX Health centers operate under the name and brand Infusion Express in Kansas City, Philadelphia, Chicago, and San Francisco. | $100M / Series F / Sep 21, 2021 | ||
| Clinical Ink, Inc. provides eSource solutions for the clinical trials industry. It offers SureSource, an electronic source solution that allows users to record comments, explanations, and validated source data on protocol-specific eSource documents, as well as captures the data required by the protocol. The company also provides an electronicsource record (ESR) for clinical trials that provides cleaner data. In addition, it offers hosting services. Clinical Ink was founded in 2006 and is based in Winston-Salem, North Carolina. | Venture - Series Unknown / Dec 03, 2020 | ||
| Ginger is a telemental health provider delivering evidence-based behavioral health coaching, therapy, and psychiatry from a smartphone. Ginger's on-demand system brings together behavioral health coaches, therapists, and psychiatrists, who work as a team to deliver personalized care, right through your smartphone. The app provides members withaccess to the support they need within seconds, 24/7, 365 days a year. Millions of people have access to Ginger through leading employers, health plans, and its network of partners. | $50M / Series D / Aug 06, 2020 | ||
| OncoHealth is a leading digital health company dedicated to helping health plans, employers, providers, patients, and life science researchers navigate the physical, mental and financial complexities of cancer through technology enabled services and real-world data analytics. Supporting more than 7 million people in the US and Puerto Rico,OncoHealth offers digital solutions for treatment review, real-world evidence, and virtual care across all cancer types. | $28M / Series C / May 26, 2020 | ||
| Lightship is a provider of enterprise-level, direct-to-patient clinical research solutions. The company engages patients at home from recruitment through completion and eliminates the hurdles and inefficiencies of traditional approaches. Founded in 2018, Lightship is based in El Segundo, California. | $20M / Series A / Feb 03, 2020 | ||
| IVX Health (IVXpress, Inc.) is a leading provider of infusion and injection therapy for those with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis and other conditions.IVX Health centers are conveniently located in the communities where patients live and offer flexible scheduling, includingevenings and weekends. Patients relax in their own private suite, equipped with high-speed Wi-Fi, a flat screen TV, and comfortable recliners with room for guests. IVX Health centers operate under the name and brand Infusion Express in Kansas City, Philadelphia, Chicago, and San Francisco. | $22.5M / Series C / Aug 05, 2019 | ||
| OncoHealth is a leading digital health company dedicated to helping health plans, employers, providers, patients, and life science researchers navigate the physical, mental and financial complexities of cancer through technology enabled services and real-world data analytics. Supporting more than 7 million people in the US and Puerto Rico,OncoHealth offers digital solutions for treatment review, real-world evidence, and virtual care across all cancer types. | $21M / Series B / Nov 05, 2018 | ||
| IVX Health (IVXpress, Inc.) is a leading provider of infusion and injection therapy for those with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis and other conditions.IVX Health centers are conveniently located in the communities where patients live and offer flexible scheduling, includingevenings and weekends. Patients relax in their own private suite, equipped with high-speed Wi-Fi, a flat screen TV, and comfortable recliners with room for guests. IVX Health centers operate under the name and brand Infusion Express in Kansas City, Philadelphia, Chicago, and San Francisco. | $13.5M / Series B / Oct 31, 2017 | ||
| See all 17 investments → | |||
Co-Investors
About McKesson Ventures
McKesson Ventures they help entrepreneurs in healthcare technology and services to create efficient health care delivery systems for key stakeholders on all sides of the health care economy.
McKesson Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carrie Williams
Vice President and Partner
|
|||
|
Dave Schulte
SVP, Managing Director
|
|||
Ed Albrektsen
Director, Vendor Solutions & Audit
|
|||
Jennifer Carter
Vice President, Portfolio Development; Partner & Vice President Venture Operations
|
|||
Michelle Snyder
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dave Schulte invest in?
Dave Schulte invests primarily in Health Care, Information Technology and Software startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dave Schulte?
Public channels for Dave Schulte include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dave Schulte last invest?
The most recent investment recorded for Dave Schulte closed in Jan 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
